NCT02771730 - Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

February 28, 2017

Study Completion Date

February 28, 2017

Conditions

Healthy VolunteerHIV Vaccine

Interventions

BIOLOGICAL

Ad4-mgag

A live replication-competent Adenovirus type-4 vector encoding a mosaic HIV Gag antigen, delivered orally by enteric-coated capsules.

BIOLOGICAL

Ad4-EnvC150

A live replication-competent Adenovirus type-4 vector encoding an HIV clade C Env protein (gp150 1086.C), delivered orally by enteric-coated capsules.

OTHER

Placebo Comparator

Oral sucrose capsules

BIOLOGICAL

AIDSVAX B/E

300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein adsorbed onto 600 mcg of aluminum hydroxide gel adjuvant, administered intramuscularly (IM).

Trial Locations (1)

94063

Paxvax, Redwood City